Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Anavex Life Sciences Corp.

http://www.anavex.com

Latest From Anavex Life Sciences Corp.

Anavex Reveals Positive Phase III Data In Rett Syndrome But A Surprise Endpoint

The endpoint used in the AVATAR trial was different than the one investors had expected; management said the change was made to satisfy the US FDA.

Neurology Clinical Trials

Acadia’s Trofinetide Shows Efficacy In Rett Syndrome, But Safety Looks Shaky

Trofinetide could be the first approved drug for Rett patients after hitting both co-primary endpoints in a Phase III trial, but high rates of diarrhea and vomiting raise questions.

Clinical Trials Rare Diseases

Aduhelm Approval Boosts Other Alzheimer’s Drug Developers

Biogen/Eisai’s aducanumab, as the first disease-modifying therapy and setting a precedent for accelerated approval, lifted the entire Alzheimer’s field.

Approvals Business Strategies

Start-Up News

Noteworthy news from medtech start-ups. This month we profile Ibris, which is developing prognostics to identify breast cancer patients in need of chemotherapy, and Delphinus Medical Technologies, whose platform enables 3-D full breast ultrasound.

Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Anavex Australia Pty Ltd.
UsernamePublicRestriction

Register